Replies to post #171263 on Biotech Values

[DewDiligence]

ABBV/ENTA—Therefore, the SVR12 for GT1b naive for Pearl III (450+267+333) must be between 95-98%. The figures for GT1b [treatment-experienced] (Pearl II) must be between 90% and 97%.

Are you referring to the ribavirin arms or the non-ribavirin arms of PEARL-2 and PEARL-3? The purpose of these two trials is to find out if ribavirin is needed in TE GT1b and TN GT1b, respectively (#msg-94927196).